CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
|Generic Name||Brentuximab vedotin|
|Indication||Systemic Anaplastic Large Cell Lymphoma|
|Funding Request||For second-line treatment of sALCL patients - i.e. after failure of at least one prior multi-agent chemotherapy regimen|
|Pre Noc Submission||No|
|NOC Date||February 1, 2013|
|Manufacturer||Seattle Genetics, Inc.|
|Sponsor||Seattle Genetics, Inc.|
|Submission Date||March 15, 2013|
|Submission Deemed Complete||March 22, 2013|
|Prioritization Requested||Not Requested|
|Stakeholder Input Deadline ‡||April 2, 2013|
|Check-point meeting||May 8, 2013|
|pERC Meeting||September 19, 2013|
|Initial Recommendation Issued||October 3, 2013|
|Feedback Deadline ‡||October 18, 2013|
|pERC Reconsideration Meeting||November 21, 2013|
|Final Recommendation Issued||December 5, 2013|
|Notification to Implement Issued||December 20, 2013|
|Clarification||Time required for the submitter to provide additional economic information has impacted the review timeline.|
|Therapeutic Area||Systemic Anaplastic Large Cell Lymphoma|
|Recommendation Type||Reimburse with clinical criteria and/or conditions|
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.